Donald J. Santel
Donald Santel has 35+ years of experience in the biotechnology/biopharmaceutical and medical device industries. He has comprehensive experience as an entrepreneur and executive leader, cumulatively raising 236M privately and 223M in public companies. Donald J. Santel has served on the Adicet Bio Board of Directors. Prior to Adicet Bio, Mr. Santel was a member of the board of directors and the Chief Executive Officer of Hyperion Therapeutics, a biopharmaceutical company he joined in 2008, brought public in 2012, and sold to Horizon Pharma in 2015. Prior to Hyperion, Mr. Santel was CEO of CoTherix, Inc., a biopharmaceutical company he co-founded in 2000, brought public in 2004, and sold to Actelion in January 2007. Prior to joining CoTherix, Mr. Santel was employed by or consultant to several medical device companies, including Reflow, Inc., Cardiac Pathways Corporation and Medtronic, Inc. Mr. Santel holds an M.S. in electrical engineering from the University of Minnesota and a B.S.E. in biomedical engineering from Purdue University.